<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000649780"><TermName>yttrium Y 90 epratuzumab tetraxetan</TermName><TermPronunciation>(IH-tree-um … eh-pruh-TOO-zoo-mab teh-TRAK-seh-tan)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of certain types of B-cell cancer. Epratuzumab is a monoclonal antibody that binds to a protein called CD22, which is found on the surface of B cells. It is linked to a radioactive substance called yttrium Y 90, which may help kill cancer cells. Yttrium Y 90 epratuzumab tetraxetan is a type of radioimmunoconjugate.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000736891" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;yttrium Y 90 epratuzumab tetraxetan&quot;" language="en" id="_3"/><MediaLink ref="CDR0000736890" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;itrio Y 90 epratuzumab tetraxetán&quot;" language="es" id="_4"/><SpanishTermName>itrio Y 90 epratuzumab tetraxetán</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de ciertos tipos de cáncer de células B. El epratuzumab es un anticuerpo monoclonal que se une a una proteína que se llama CD22, que se encuentra en la superficie de las células B. Se enlaza con una sustancia radiactiva que se llama itrio Y 90, que podría ayudar a destruir células cancerosas. El itrio Y 90 epratuzumab tetraxetán es un tipo de radioinmunoconjugado.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2012-05-03</DateFirstPublished></GlossaryTerm>
